RxDoctor Payments Data

Angelia Jackson, APRN

Family · Louisville, KYNPI 1437580057

Payments from drug & device makers

$1,926in general payments, 2019–2025

Across 129 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$772
  • Novo Nordisk$360
  • Biohaven Pharmaceutical Holding Company Ltd.$144
  • Lilly USA, LLC$119
  • Exact Sciences$92
  • Phathom Pharmaceuticals, Inc.$86
  • plus $352 from 12 others

What the payments were for

  • Food & beverage$1,926100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,926 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$82,900
Medicare patients
311
Services billed
2,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$44,348
FarxigaDapagliflozin Propanediol25$16,468
RybelsusSemaglutide15$14,418
JanuviaSitagliptin Phosphate21$13,383
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,672
DuleraMometasone/Formoterol11$3,700
Mesalamine ErMesalamine11$3,144
Atorvastatin Calcium402$2,905
Omeprazole116$1,387
SynthroidLevothyroxine Sodium12$1,357
Levothyroxine Sodium132$1,270
Albuterol Sulfate HfaAlbuterol Sulfate44$1,176
Metoprolol Succinate67$1,035
Rosuvastatin Calcium72$820
Potassium Chloride31$782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Dulera$21$17,08332 claims
Novo NordiskRybelsus$360$14,41815 claims
GSKTrelegy Ellipta$47$6,67211 claims
AbbVieSynthroid$772$1,35712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →